To isolate genes with different expression levels in human esophageal SCC, SSH and reverse Northern were performed between cancer tissue and its normal counterpart. Among the differentially expressed genes identified, we report here cDNA corresponding to a 0.88 kb mRNA (NMES1), whose expression was observed in all 36 adjacent normal esophageal mucosae, while 31 (86%) matched cancer tissues showed a marked reduction or complete lack of its expression. Sequence analysis of its full-length cDNA revealed a gene encoding a predicted polypeptide of 9 kDa. Northern blot showed that NMES1 was distributed mainly in the alimentary tract. The gene was mapped to 15q21.1 by screening the GenBridge 4 RH panel. Immunohistochemistry confirmed the downregulation of NMES1 in esophageal SCC at the protein level and showed that it is a nuclear protein. In situ hybridization revealed its different expression during mouse embryonic development, especially in bone, brain, stomach and intestine. The negative correlation of NMES1 expression with esophageal oncogenesis suggests its suppressive role in tumorigenesis of the esophagus, while the precise function of NMES1 still needs further investigation.
Cancer of the esophagus ranks among the 10 most frequent cancers in the world and is the second most common cancer in China. [1] [2] [3] Due to relatively late diagnosis and poor efficacy of treatment, the mortality rate is very similar to the incidence rate. The 5-year survival rate is below 10%. 4 In northern China (Lin Xian), where the highest incidence rate of esophageal cancer in the world is found, about 90% of esophageal cancers are SCCs. Epidemiologic studies revealed that, different from adenocarcinomas that developed from Barrett's esophagus, SCCs were more related to dietary habits, tobacco smoking and alcohol drinking. Familial aggregation was also found in SCC, which suggested that genetic alterations play an important role in tumorigenesis of the esophagus. [1] [2] [3] [4] High frequency of LOH has been found on chromosomes 3, 7 and 9. 4 -6 To date, no susceptibility genes for esophageal cancer have been identified. Mutations in p53 and p16 and overexpression of cyclin D1 and EGFR have been found in SCC. 4 Using commercially available microarray membranes, a set of known genes differentially expressed in SCC has been identified in our lab as well as elsewhere. [7] [8] [9] [10] [11] [12] These include overexpression of CDC25B, matrix metalloproteinases, Notch1, Fra-1, Neogenin, CASK, Id-1, etc. and downregulation of cytokeratin-4, cytokeratin-13, BAD, IL-1 receptor antagonist, etc . However, the molecular biology of esophageal SCC remains poorly defined.
In our study, a PCR-based cDNA SSH method 13 was employed to characterize new genes differentially expressed in esophageal SCC. A novel gene, NMES1, was substantially downregulated in esophageal cancers. RH screening localized NMES1 on chromosome 15q21.1. Immunochemic staining showed that the NMES1-encoded protein is a nuclear protein. Northern blot indicated that NMES1 is mainly distributed in the normal adult gut. Furthermore, in situ hybridization studies showed expression of NMES1 in bone, brain, intestine and stomach during mouse embryonic development.
MATERIAL AND METHODS

Esophageal and colon tissues
Esophageal cancer and matched adjacent normal mucosa were taken from patients who had not been treated with radiotherapy or chemotherapy before surgery. Fresh samples were dissected manually to remove mixed connective tissues and stored in liquid nitrogen immediately. Total RNA for SSH was from 2 patients with moderately differentiated esophageal SCC, a 61-year-old man and a 69-year-old woman. For Northern blot and RT-PCR, matched tumor and adjacent normal tissues were from 36 esophageal SCC patients, 21 male and 15 female. The age range of these patients was 45-72 years. In regard to pathologic grade, 19 were moderately differentiated and 17 were highly differentiated SCC. Among 12 pairs of colon cancer samples for semiquantitative RT-PCR analysis, 5 were highly differentiated, 6 moderately differentiated and 1 poorly differentiated. 
SSH
SSH was performed with the PCR-Select cDNA Subtractive Kit (Clontech) as described by the manufacturer with the following modification: for ease of cloning into the plasmid vector, the 2R oligo was replaced by 2Rϩ( 5Ј-ttgtcgacagcgtggtcgcggccgaggt-3Ј) with a SalI recognition site at its 5Ј end. For subtraction, cDNA from normal mucosa was taken as tester and cDNA from cancer tissue as driver. All PCR products generated by subtraction were digested with NotI and SalI and subcloned into a pBluescript SK(-) vector (Stratagene, La Jolla, CA).
Reverse northern screening
A total of 180 recombinant clones were picked individually into 200 l LB medium with 100 g/l ampicillin. After incubation, the bacterial culture was used as template to amplify the cloned inserts with T3 and T7 primers (which flank the multiple cloning sites of the vector) and 100 ng of the PCR products were denatured and alkaline-blotted onto 2 nylon membranes in parallel. cDNA probes were synthesized from 5 g normal and cancer total RNA by reverse-transcription in the presence of 32 P-dATP. Hybridization was carried out in ExpressHyb hybridization solution (Clontech) with equivalent amounts of probe with approximately equal specific activity. After hybridization at 65°C overnight, filters were washed and exposed to X-ray film at -80°C for 2 days and the signals of parallel clones were compared.
Northern blotting
Total RNA (30 g) from tumor tissues and matched normal mucosa was used for Northern blot analysis. The expression pattern in multiple adult human tissues was analyzed with Human Adult Normal Tissue Total RNA Northern Blot I, II (Biochain, Hayward, CA), as the manufacturer described.
Full-length cDNA acquirement
To get the 5Ј extent of the cDNA of NMES1, RACE was performed with the SMART RACE system (Clontech) using the gene-specific primers 15GSP1 (5Ј-tgcagttattgctgcactcctttaattc-3Ј) and 15GSP2 (5Ј-tgtcgactgtagcagaagcagttccgcac-3Ј). The amplified cDNA fragment was then cloned into pGEM-T Easy vector (Promega) and sequenced. End-to-end PCR was performed with primers 15FULf (5Ј-gtccaggtgagtctcccatct-3Ј) and 15FULr (5Ј-tatacctaatctttgagaaatcttgca-3Ј) and cloned into pGEM-T Easy vector to acquire the full-length cDNA clone.
Semiquantitative RT-PCR
Primer sequences for NMES1 were 5Ј-GGTTCAAATG-TATTTTTCTCCCAT-3Ј (sense) and 5Ј-TTTGGGCTCTGGATA-AGGAAT-3Ј (antisense). First-strand cDNA was synthesized from 5 g total RNA using the Superscript preamplification system for first-strand cDNA synthesis (Life Technologies, Rockville, MA). An aliquot of one-twentieth of the product was used as template in a 25 l PCR containing 1 ϫ PCR buffer, 1.5 mM MgCl 2 , 200 M dNTPs, 1.5 U Taq polymerase (Life Technologies) and 40 M gene-specific primers under the following conditions: 94°C for 5 min, followed by 25 cycles each of 94°C for 20 sec, 60°C for 30 sec and 72°C for 1 min. The housekeeping gene GAPDH was chosen as internal control and amplified in the same aliquot. All 20 l RT-PCR products were resolved on a 1.2% agarose gel. Electrophoretic images were scanned by a Fluor-S MultiImager (BioRad, Richmond, CA), and the original intensities of specific bands were quantified by Multi-Analyst software (Bio-Rad). Data were compared after normalization by the intensity of GAPDH.
In situ hybridization during mouse embryonic development
In situ hybridization was performed with NMES1 3Ј region as a probe, the probe was synthesized with digoxigenin ␥-UTP (Boehringer-Mannheim, Mannheim, Germany). Mouse embryos in utero were collected on different days postcoitus. Embryos were fixed in paraformaldehyde and embedded in paraffin, 6 m sections were mounted on glass slides and the slides were soaked in 2% aminopropyltriethoxysilane and incubated at 42°C overnight to facilitate the adherence of the section to slides. Sections were then dewaxed and rehydrated, treated with 10 g/ml proteinase K (10 min in room temperature) and acetylated in 0.56% acetic anhydride (10 min at room temperature), followed by prehybridization in a solution of 50% formamide, 4 ϫ SSPE, 20 mM DTT and 10 ϫ Denhardt's solution at 50°C for 12-16 hr and hybridization with labeled antisense probe in the presence of Escherichia coli tRNA in 20 l prehybridization solution at 50°C for 36 hr. After hybridization, sections were briefly rinsed and subsequently incubated with anti-digoxigenin (1:500) (Boehringer-Mannheim) at room temperature for 90 min. Postantibody washes and staining were carried out as described by Wilkinson. 14 The sense probe was used as a negative control.
RH mapping
Gene-specific primers 15GSP3 (5Ј-ggctctggataaggaattaaagg-3Ј) and 15GSP4 (5Ј-tgagaaatcttgcacaaatgg-3Ј), which were picked from the 3Ј-UTR of the gene, were used in the screening of the 
Antibody generation
A peptide with the sequence KRKELIPLVVFMTVAAGGASS (amino acid residues 9 -29 of the NMES1 sequence) was synthesized and used to immunize rabbits to get the antibody; after 3 rounds of injection, rabbits were boostered and the serum was collected.
Immunohistochemic staining
Sixteen tissue samples were obtained by surgical excision, and all were diagnosed as SCC. The distal incision tissue of every sample was used as the normal counterpart; 4 m paraffin-embedded sections were dewaxed in xylene, rehydrated in ethanol and blocked for endogenous peroxidase by incubation with H 2 O 2 . Following antigen retrieval, by microwaving in a citrate buffer (pH 6.0) for 15 min, slides were incubated with NMES1 antibody at a 1:100 dilution overnight at 4°C. The second (peroxidase) step were performed using the UltraSensitive S-P (Streptavidin-Peroxide) Kit (Maxim Biotech, Fuzhou, People's Republic of China) according to the manufacturer's protocol. DAB was used as the chromogen and hematoxylin as the counterstain. Primary antibody was replaced by nonimmune serum (Maxim Biotech) for negative controls.
RESULTS
SSH and reverse northern
A total of 373 SSH clones were generated, with cDNA insert sizes ranging 150 -1,000 bp; 180 clones were randomly picked for further characterization by reverse Northern. By comparing the clone signals on parallel membranes, responding transcripts with different expression levels were characterized. Eight clones with significantly different expression levels were chosen for further analysis; sequence analysis revealed that 7 were known genes and 1 was a previously uncharacterized gene whose expression was lower in the tumor tissue compared to the normal tissue.
Northern blot analysis and RT-PCR
Northern blot analysis was carried out to confirm the different expression levels of the novel gene. In 16 pairs of matched tissues, expression was observed in all normal esophageal mucosae, while 15 of the matched tumor tissues showed a marked reduction or complete lack of expression. Thus, the gene is designated NMES1 (normal mucosa of esophagus specific 1). The time needed for visualization of the hybridization signal was 4 days, indicating that it is expressed at low abundance in normal epithelia of the esophagus (Fig. 1a) .
Semiquantitative RT-PCR was performed to verify the differential expression in esophageal SCC and colon cancer. In 20 pairs of matched esophageal tissue samples, low expression of NMES1 was detected in 16 pairs of esophageal cancer tissue compared to normal counterparts. In 12 pairs of matched colon cancer samples, low expression was observed in 9 pairs of cancer tissues compared to normal counterparts (Fig. 1b) .
Distribution pattern of NMES1 in adult normal tissues
Northern blot in multiple adult tissues was performed to test the NMES1 expression pattern. As shown in Figure 2 , NMES1 was distributed mainly in the esophagus, stomach, small intestine, colon (lane 9 -12) and placenta (lane 14), with very weak expression in lung (lane 5); no expression was observed in the heart, brain, kidney, liver, pancreas, spleen, muscle, uterus, bladder and adipose. Only 1 transcript, 900 bp, was observed in the expressing tissues.
Isolation of NMES1 full-length cDNA
The SSH clone of NMES1 contained a partial cDNA of 384 bp. By homology search of the existing ESTs, a sequence of 83 bp was found to fill in the 3Ј region, including the polyadenylation signal and poly(A) tail. Gene-specific primers were designed from the 5Ј region for 5Ј-RACE. Three independent RACE experiments were carried out, and a similar 500 bp fragment was obtained and cloned. Sequence analysis showed that the 3 independent clones were identical and contained the expected overlap with the original sequence. Full-length cDNA was obtained by end-to-end PCR with primers nearest to the 5Ј or 3Ј end, using newly synthesized first-strand cDNA of normal adult human esophagus as template. Further analysis of the full-length clone confirmed the complete sequence. This cDNA contains an ORF encoding a protein of 83 amino acids, a 5Ј-UTR of 189 bp, an in-frame stop codon upstream of the ORF and a 3Ј-UTR of 445 bp. The sequence around the start codon is in accordance with the Kozak box, 15 and an in-frame stop codon exists upstream of the first methionine, showing integrity of the ORF. Further analysis predicted an O-glycosylation site at Thr 53 and an N-myristoylation site at amino acid residues 25-30 (GGASSF). The nucleotide sequence of NMES1 has been deposited in the GenBank/EMBL database with the accession number AF228422.
The sequence was compared to the GenBank/EMBL database and did not match any previously reported gene, but the predicted amino acid sequence demonstrates an overall of 31-34% identity with the mouse, bovine and human NADH-ubiquinone oxidoreductase MLRQ subunit. However, the NADH-ubiquinone oxidoreductase MLRQ subunit is usually expressed at high levels in tissues such as heart and muscle, whereas no expression signal could be detected in these tissues for the NMES1 gene. Furthermore, we have evidence that the NADH-ubiquinone oxidoreduc- tase MLRQ subunit was upregulated in esophageal SCC compared to its normal counterpart (data not shown).
NMES1 embryonic expression pattern
In situ hybridization was performed to reveal the gene expression pattern during mouse embryonic development. Expression was first visible during gastrulation at 8 days postcoitus in the ossification center and spinal cord (Fig. 3a) ; from this stage up to the birth, expression extended throughout the bone tissue and strong expression was detected in the vertebrae (Fig. 3b,e ). Another major site of expression was detected in the developing brain (Fig. 3b,f) , including the prosencephalon, mesencephalon, diencephalons, telencephalon and rhombencephalon. NMES1 also was strongly expressed in the intestine (Fig. 3b) ; very strong expression was detected in the stomach (Fig. 3c) . Faint expression was observed in lung tissue at 16 days postcoitus. No signal was detected in liver and heart tissue.
Chromosomal localization of NMES1
By GenBridge 4 screening and RHMAPPER program analysis, NMES1 was located to 15q21.1 on the cytogenetic map, between 113 and 124 cR on the GenBridge 4 RH map and about 40 kcM from the telomere of 15p on the linkage map. The relative location of NMES1 to other STS markers on the cytogenetic map, the GenBridge 4 RH map and the linkage map is shown in Figure 4 .
Immunohistochemic distribution of NMES1 in matched esophageal cancer tissue samples
Immunohistochemic staining was performed to show the expression and distribution of NMES1 at the protein level in matched esophageal SCC tissue samples. Expression was mainly localized in the stratified squamous epithelium of normal esophagus, with some expression in fibroblast cells and inflammatory cells in the stroma as well. In the matched normal tissue samples, positive staining was obviously present in the nucleus of the basal cell layer; positive cells could also be seen in other layers of the esophageal squamous epithelium. However, in the cancer tissues, very low NMES1 expression in the cancer nest was observed (Fig.  5) . Among the 16 pairs of samples tested, all normal samples showed high expression of NMES1, whereas 13 matched cancer samples showed very low expression in the cancer nest and 3 of these showed some positive staining in the cancer nest as well.
DISCUSSION
Using SSH and reverse Northern, we have identified a novel gene, NMES1, which is differentially expressed in SCC of the esophagus. Northern blot, RT-PCR and immunohistochemistry showed marked downregulation or complete lack of its expression in primary SCC of the esophagus compared to adjacent normal mucosa. This suggests that NMES1 may play a suppressive role in esophageal carcinogenesis. Reduction of NMES1 was found in SCC at both the RNA level and protein levels, which suggests that downregulation may be due to alterations at the transcriptional or genomic level. The cause of this downregulation, e.g., epigenetic mutations, hypermethylation or LOH, remains to be investigated.
As a novel gene, no homology could be found with the NMES1 protein in the database. Northern blot and in situ hybridization showed that NMES1 was expressed in adult human normal esophagus, stomach, intestine and colon as well as in mouse embryonic stomach and intestine. This indicates that NMES1 is related to both embryonic development and adult alimentary tract function. NMES1 expression was detected in developing brain (mouse) but not in adult brain (human), which suggests that it may play a role in early brain development and may be turned off in later stages. In addition, NMES1 was expressed from 8 days postcoitus in the ossification center and spinal cord and extended to the whole bone tissue until birth. This suggests that it plays an important role in the development of bone tissue. Whether NMES1 also plays a role in adult bone tissues needs further investigation.
We also introduced 2 modifications into the original SSH method. 13, 16, 17 Firstly, reverse Northern was used in the screening of SSH clones. Reverse Northern (in which chosen clones are dotted on membranes and cDNA derived from RNA of normal or tumor tissues is used as probe) enables exclusion of most of the false-positive clones in a single hybridization, therefore substan- tially decreasing the false-positive rate of SSH from 50 -90% to 20 -30%. Secondly, a PCR-based method was used to synthesize double-strand cDNA for SSH. Starting material was reduced from conventional polyA ϩ RNA to total RNA using a low cycle of PCR amplification. Meanwhile, the bias in abundance of the mRNA population produced by PCR amplification was monitored and limited using cDNA directly derived from any other polyA ϩ RNA as control. Identification of NMES1 as well as other differentially expressed genes in our laboratory attested to the validity of this system. 9, 10 Since most of the precancerous tissues were obtained by biopsy or microdissection, which provide only a limited amount of samples, this method will be extremely useful in identifying differentially expressed genes in these tissues.
